Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

EMA Recommends Granting a Conditional Marketing Authorisation for Daratumumab

It is intended for the treatment of relapsed and refractory multiple myeloma
04 Apr 2016
Haematologic malignancies;  Anticancer agents & Biologic therapy

On 1 April 2016, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product daratumumab (Darzalex), intended for the treatment of relapsed and refractory multiple myeloma. Darzalex was designated as an orphan medicinal product on 17 July 2013.

The applicant for this medicinal product is Janssen-Cilag International N.V.

Darzalex will be available as a 20 mg/ml concentrate for solution for infusion. The active substance of Darzalex is daratumumab, an IgG1κ human monoclonal antibody (ATC code: L01XC24) that binds to the CD38 protein and potently inhibits the in-vivo growth of CD38-expressing tumour cells.

The benefit with Darzalex is its ability to achieve responses in patients with relapsed and refractory multiple myeloma.

The most frequently reported adverse reactions were infusion-related reactions, which occurred in 48% of patients. Other frequently reported adverse reactions (in ≥20% of patients) were fatigue, pyrexia, cough, nausea, back pain, upper respiratory tract infection, anaemia, neutropenia and thrombocytopenia.

The full indication is:

"Darzalex as monotherapy is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.”

Darzalex should be administered by a healthcare professional, in an environment where resuscitation facilities are available.

Detailed recommendations for the use of this product will be described in the summary of product characteristics, which will be published in the European public assessment report and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

Last update: 04 Apr 2016

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.